
ISO 17593:2022
ISO 17593:2022 Clinical laboratory testing and in vitro medical devices – Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy
CDN $351.00
Description
This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.
This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).
This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.
This document is not applicable to:
-   in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;
-   non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);
-   a comprehensive evaluation of all possible factors that can affect the performance of these systems;
-   the medical aspects of oral-anticoagulation therapy.
Edition
2
Published Date
2022-03-11
Status
PUBLISHED
Pages
53
Format 
Secure PDF
Secure – PDF details
- Save your file locally or view it via a web viewer
- Viewing permissions are restricted exclusively to the purchaser
- Device limits - 3
- Printing – Enabled only to print (1) copy
See more about our Environmental Commitment
Abstract
This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.
This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).
This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.
This document is not applicable to:
-   in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;
-   non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);
-   a comprehensive evaluation of all possible factors that can affect the performance of these systems;
-   the medical aspects of oral-anticoagulation therapy.
Previous Editions
Can’t find what you are looking for?
Please contact us at:
Related Documents
-

ISO 10993:2021 Biological evaluation of medical devices – Part 12: Sample preparation and reference materials
CDN $233.00 Add to cart -

ISO 10993:2025 Biological evaluation of medical devices – Part 4: Selection of tests for interactions with blood – Amendment 1
CDN $32.00 Add to cart -

ISO 10993:2022 Biological evaluation of medical devices – Part 2: Animal welfare requirements
CDN $173.00 Add to cart -

ISO 11796:2023 Biological evaluation of medical devices – Requirements for interlaboratory studies to demonstrate the applicability of validated in vitro methods to assess the skin sensitization of medical devices
CDN $273.00 Add to cart







